Asia
Takeda said that Phase III PANTHER, which studied the effectiveness of pevonedistat for different types of leukemia, did not produce significant results in terms of event-free survival.
Between April 2020 and today, the executive board of Kyowa Kiran North America (KKNA) has grown from being predominantly male to a 50/50 gender split.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
Two former executives of JHL Biotech were indicted on charges of orchestrating the theft of trade secrets, wire fraud exceeding $101 million, and money laundering.
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
Early data from a Phase III study for COVID-19 shows significant promise with its combo therapy reduced death and hospitalization in trial patients at high risk of progression by 78%.
The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
PRESS RELEASES